These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 12678411)
1. In vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus. Toyokawa M; Asari S; Nishi I; Horikawa M; Tsukamoto H; Sunada A; Ueda A; Iwatani Y J Chemother; 2003 Feb; 15(1):31-6. PubMed ID: 12678411 [TBL] [Abstract][Full Text] [Related]
2. [Combination effect of arbekacin and cefepime on mixed culture of MRSA and P. aeruginosa]. Araake M; Hara T; Miyata A; Tani M; Ogawa H Jpn J Antibiot; 2001 Feb; 54(2):69-78. PubMed ID: 11338680 [TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the activity and effects of combinations of various antibacterial agents against methicillin-resistant Staphylococcus aureus in vitro]. Kouda M; Homma S; Udagawa I; Fukuhara J; Takeuchi M; Tamura K Jpn J Antibiot; 2000 Mar; 53(3):171-8. PubMed ID: 10834148 [TBL] [Abstract][Full Text] [Related]
4. [The in vitro antibacterial activity of cefozopran against clinically isolated bacteria]. Higurashi Y; Okuzumi K; Yoneyama A; Nakahara K Jpn J Antibiot; 1997 Dec; 50(12):907-16. PubMed ID: 9545668 [TBL] [Abstract][Full Text] [Related]
5. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides. Betts JW; Abdul Momin HF; Phee LM; Wareham DW J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156 [TBL] [Abstract][Full Text] [Related]
6. [Reliability of disc-diffusion susceptibility testing for arbekacin, vancomycin and teicoplanin against methicillin-resistant Staphylococcus aureus]. Kouda M; Homma S; Udagawa I; Tamura K; Fukuhara J; Takeuchi M Jpn J Antibiot; 1999 Dec; 52(12):681-9. PubMed ID: 10695023 [TBL] [Abstract][Full Text] [Related]
7. [Combination effect between panipenem and vancomycin on highly methicillin-resistant Staphylococcus aureus]. Fukuoka T; Domon H; Kakuta M; Ishii C; Hirasawa A; Utsui Y; Ohya S; Yasuda H Jpn J Antibiot; 1997 Apr; 50(4):411-9. PubMed ID: 9192249 [TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. Drago L; De Vecchi E; Nicola L; Gismondo MR BMC Infect Dis; 2007 Sep; 7():111. PubMed ID: 17888153 [TBL] [Abstract][Full Text] [Related]
9. [Combined effect of vancomycin or teicoplanin plus a beta-lactam antibiotic in mouse infection models caused by beta-lactam antibiotec-induced vancomycin resistant MRSA (BIVR)]. Hatano K; Yokota Y; Hanaki H; Sunakawa K Kansenshogaku Zasshi; 2006 May; 80(3):243-50. PubMed ID: 16780131 [TBL] [Abstract][Full Text] [Related]
11. [Combination effect of teicoplanin and panipenem on highly resistant strains of MRSA]. Utsui Y; Ishii C; Abe T; Kakuta M; Ohya S Jpn J Antibiot; 1999 Mar; 52(3):268-77. PubMed ID: 10367264 [TBL] [Abstract][Full Text] [Related]
12. [Effect of arbekacin on the production of toxic shock syndrome toxin 1 by methicillin-resistant Staphylococcus aureus]. Miyata A; Araake M; Ogawa H; Hanaki H; Hiramatsu K Jpn J Antibiot; 2001 Jul; 54(7):372-81. PubMed ID: 11560056 [TBL] [Abstract][Full Text] [Related]
13. [In vitro combination effect of pazufloxacin with various antibiotics against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus]. Maekawa M; Takahashi K; Takahata M; Minami S Jpn J Antibiot; 2002 Aug; 55(4):440-5. PubMed ID: 12378872 [TBL] [Abstract][Full Text] [Related]
14. [Activity of vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus in the period 1994-1999]. Nashev D; Toshkova K; Gavrilova V Vutr Boles; 2000; 32(2):35-40. PubMed ID: 11227664 [TBL] [Abstract][Full Text] [Related]
16. Effects of DQ-113, a new quinolone, against methicillin- and vancomycin-resistant Staphylococcus aureus-caused hematogenous pulmonary infections in mice. Kaneko Y; Yanagihara K; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S Antimicrob Agents Chemother; 2003 Dec; 47(12):3694-8. PubMed ID: 14638467 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy. Pistella E; Falcone M; Baiocchi P; Pompeo ME; Pierciaccante A; Penni A; Venditti M Infez Med; 2005 Jun; 13(2):97-102. PubMed ID: 16220029 [TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant staphylococcus aureus and enterococcus faecium in the Tohoku district of Japan. Lutfor AB; Kikuchi T; Tokue Y; Takahashi H; Shoji S; Fujimura S; Nukiwa T; Watanabe A Chemotherapy; 1998; 44(5):318-23. PubMed ID: 9732146 [TBL] [Abstract][Full Text] [Related]
19. In vitro activities of nisin alone or in combination with vancomycin and ciprofloxacin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains. Dosler S; Gerceker AA Chemotherapy; 2011; 57(6):511-6. PubMed ID: 22302084 [TBL] [Abstract][Full Text] [Related]
20. Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus. Fujimura S; Fuse K; Takane H; Nakano Y; Gomi K; Kikuchi T; Watanabe A J Infect Chemother; 2011 Feb; 17(1):30-3. PubMed ID: 20665064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]